From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment

K Swanson, E Wu, A Zhang, AA Alizadeh, J Zou - Cell, 2023 - cell.com
Machine learning (ML) is increasingly used in clinical oncology to diagnose cancers, predict
patient outcomes, and inform treatment planning. Here, we review recent applications of ML …

Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma

P Johnson, Q Zhou, DY Dao, YMD Lo - … reviews Gastroenterology & …, 2022 - nature.com
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-
related death worldwide. The treatment of HCC remains challenging and is largely …

[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

J Pascual, G Attard, FC Bidard, G Curigliano… - Annals of …, 2022 - Elsevier
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …

Evaluation of cell-free DNA approaches for multi-cancer early detection

A Jamshidi, MC Liu, EA Klein, O Venn, E Hubbell… - Cancer Cell, 2022 - cell.com
Summary In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we
evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer …

The future of early cancer detection

RC Fitzgerald, AC Antoniou, L Fruk, N Rosenfeld - Nature medicine, 2022 - nature.com
A proactive approach to detecting cancer at an early stage can make treatments more
effective, with fewer side effects and improved long-term survival. However, as detection …

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance

P Stejskal, H Goodarzi, J Srovnal, M Hajdúch… - Molecular cancer, 2023 - Springer
Background Despite advances in early detection and therapies, cancer is still one of the
most common causes of death worldwide. Since each tumor is unique, there is a need to …

Liquid biopsy enters the clinic—implementation issues and future challenges

M Ignatiadis, GW Sledge, SS Jeffrey - Nature reviews Clinical oncology, 2021 - nature.com
Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies

YMD Lo, DSC Han, P Jiang, RWK Chiu - Science, 2021 - science.org
BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …

Artificial intelligence in cancer research and precision medicine

B Bhinder, C Gilvary, NS Madhukar, O Elemento - Cancer discovery, 2021 - AACR
Artificial intelligence (AI) is rapidly resha** cancer research and personalized clinical
care. Availability of high-dimensionality datasets coupled with advances in high …

Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics

P Song, LR Wu, YH Yan, JX Zhang, T Chu… - Nature biomedical …, 2022 - nature.com
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …